MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
53.11
+2.12 (4.16%)
Sep 18, 2024, 4:00 PM EDT - Market closed
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Jorge da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, 6300 Switzerland | |
| Phone | 41 415108022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, Chief Executive Officer and Director |
| Dr. Kristian Reich | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop Ph.D. | Chief Operations Officer |
| Carla Bretes | Director Investor Relations and Business Development |
| Nicolas Mosimann | General Counsel |
| Joana Cortez | Senior Director Legal and Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
| Luciana Marques | Director of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 11, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 13, 2024 | UPLOAD | Filing |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-K/A | [Amend] Annual report |
| Apr 29, 2024 | UPLOAD | Filing |